Chronic Kidney Disease Is More Common in the Cancer Population
In a study conducted in Romania, the prevalence of CKD in patients with cancer was 11.9% compared with 8.8% in the general population.
ERA Congress
Dapagliflozin Slows FSGS Progression
Dapagliflozin, an oral SGLT2 inhibitor, decreased the risk of progression of focal segmental glomerulosclerosis compared with placebo, a subgroup analysis of the DAPA-CKD trial showed.
Kidney Stone Risk Higher Among Men Than Women
Modifiable risk factors accounted for only a fraction of the difference in stone rates between the sexes, according to investigators.
Sarcopenia Common, Potentially Life-Threatening in Nondialysis CKD
The prevalence of CKD-related sarcopenia may be higher than ageing-related sarcopenia.
Belimumab Shows Longer-Term Safety, Efficacy in Lupus Nephritis
The proportion of patients with lupus nephritis achieving renal response with belimumab increased during a 6-month extension study.
IL-6 Levels Linked With Progression of Diabetic Kidney Disease
In a small trial, patients with the highest tertile of IL-6 experienced significantly faster progression of diabetic kidney disease.
Renoprotective Effect of SGLT2 Inhibitors Mediated Largely by Hematocrit
Increases in the proportion of red blood cells mediates the reduction in renal risks associated with SGLT2 inhibitor therapy in patients with type 2 diabetes and cardiovascular disease, a study found.
Cardiovascular Risk Differs for Stone Formers With ESKD
Among patients with nephrolithiasis or urolithiasis, the cardiovascular event rate was 74.4 per 1000 person-years.
Male Sex Ups Death Risk in Patients With CKD Hospitalized With COVID-19
Male sex is independently associated with a nearly 2-fold increased risk for in-hospital death, among patients with CKD.
Switching to Twice-Weekly Hemodialysis Can Be Done Safely
In a community-based dialysis program, nearly 10% of patients successfully converted from 3 to 2 hemodialysis sessions per week.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ERA Congress
Loading... 
Loading...